Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

Journal of Infectious Diseases

Volumn 191, Issue 6, 2005, Pages 825-829

  Sanne, Ian ^a   Mommeja Marin, Herve ^d   Hinkle, John ^d   Bartlett, John A ^c   Lederman, Michael M ^e   Maartens, Gary ^b   Wakeford, Charles ^d   Shaw, Audrey ^d   Quinn, Joseph ^d   Gish, Robert G ^f   Rousseau, Franck ^d  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d GILEAD SCIENCES INC   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ABDOMINAL PAIN; ADULT; ALBUMIN BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MEAN CORPUSCULAR VOLUME; MULTICENTER STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK FACTOR; SOUTH AFRICA; VIRUS LOAD; VOMITING;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LIVER; MALE; NEVIRAPINE; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 20044382589     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428093     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. New data show continued decline in AIDS deaths. 31 August 1999. Available at: http://www.cdc.gov/od/oc/ media/pressrel/r99083/htm (Accessed 7 February 2005).
2. Podzamcer D, Fumero E. The role of nevirapine in the treatment of HIV-1 disease. Expert Opin Pharmacother 2001; 2:2065-78.
3. Harris M, Montaner JSG. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol 2000; 10:217-29.
4. Wit FWNM, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence and risk factors for severe hepatotoxicity associated with antiretroviral therapy. J Infect Dis 2002; 186:23-31.
5. Serious adverse events attributed to nevirapine regimens for post exposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep 2001; 49:1153-6.
6. Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor [abstract PL 9.3]. AIDS 2000; 14(Suppl 4):S12.
7. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-85.
8. World Health Organization (WHO), HIV/AIDS Department. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach: executive summary. Geneva: WHO, 2002.
9. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35:182-9.
10. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124-9.
11. de Requena DG, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity associated with nevirapine. AIDS 2002; 16:290-1.
12. De Maat MM, Ter Heine R, Mulder JW, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59:457-62.
13. De Maat MM, Huitema AD, Mulder JW, Meenhorst PL, Van Gorp EC, Beijen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1 infected individuals, Br J Clin Pharmacol 2002; 54:378-85.
14. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34(Suppl 1):S21-33.
15. Viramune tablets and oral suspension, US package insert. Ingelheim, German: Boehringer Ingelheim.